We would love to hear your thoughts about our site and services, please take our survey here.
Lithium price will certainly have been used by prospective partners to tip the deal balance in their favour: check the lowball offer for ALL that was rejected recently. Demand from China has dipped markedly. Europe and the West in general are slow to change from ICE, not helped by global events. SP here has held up pretty well tho', and the market appears to appreciate that the right partnership deal is going to take time in present conditions
Thanks. The creditors want their debt paid off so resuming shipments would appear to benefit all; maybe the creditors prefer a one off payment instead of stop/start installments. What indo sino wants is probably the key.
I bought some cadence shares when BCN was sold because i wanted to keep an interest in Sonora. Not a great move, but que sera.
Anyways, I thought that cadence had some ''income'' from the iron ore stockpile in Brazil. To paraphrase the interims from a couple of weeks back : ''shipments from the stockpile are economically viable but the secured bank creditors must approve the operation''. Presumably the creditors approved the last shipments in '22 and '21. Anybody have any info/ideas on why they won't approve them now ?
thanks
Reading this cr@p tonight.
Poster puts up useful info of company operating in similar space.......to be met with barrage of whining and childish name calling that brought precisely nothing to the discussion.
Intelligence level here has sunk lower than the share price.
Empty vessels making too much noise.
If you disagree with what someone has posted then either put up a reasoned argument against or ignore them.
Agree about the cost @neon , there should still be some market for this tech tho'. Von jacko did say about pinpointing lung cancer before treatments. Otherwise its too vague for me.
Pulmonary embolism is a big market but that has never been mentioned by the company . It may be that cyclopharm have clearance for gas exchange and thats why they can target market PE.
They need sales or some sort of commercial tie up. Amati still seem to still be on board and advising on financial options so thats some kind of positive. I'm not holding my breath tho, even for a single 10 second dose
Too depressing for me to look in here a lot, but this was a good find @neon - cyclopharms technegas gets fda approval.
I've never seen it mentioned before but obviously I should have known about it if my research had been extensive enough.
They are using radioactive tracer from technetium 99m. The disadvantage is the low dose radioactivity but that hasn't stopped cyclopharm tech being already used in 60 countries and producing revenue of 30m aus dollar last year.
One very interesting takeaway for me, on doing a bit of reading, is that cyclopharm's tech is being used primarily as a diagnostic tool for pulmonary embolism. Now, I have asked POLX at investor presentation back in February? if our tech could pick up pulmonary embolism - there was no reply. I can't see how the cyclopharm tech gives better, or more expansive imaging, beyond the chest cavity. Any thoughts anyone ?
Still no sales , and I can't believe that pharma co's developing asthma drugs don't want to buy our product - how are they evaluating lung function in patients trialling new drugs ?
The market seems to be predict failure here. I was quite impressed with new CEO's presentation but he needs sales....clock is ticking
Yes, @Laconic, that needs to be re-phrased - the hospitals need to be sure that their initial outlay and ongoing costs are going to be recouped; and more so than their current practices. The picture painted here has always been good, thats why we're here; but nobody's buying, and that needs to change pronto.
He did go into the haematology side here which was useful because it leads to far more diagnostic possibilities but they need to be able to sell some of these on the gas capability alone; the timelines and the finances are too tight to wait for that extra approval
I thought Von Jacko came across well. Was a bit vague on how this tech will save hospitals money, but at least kind of answered it. Hospital admins need to know that they can do x y and z with this tech and what money it will save them.
get orders, hope sp rises, then raise......he will have his own targets in mind
@Doppo: the person who has to deliver the good news will be speaking tomorrow at 10am on the investor meet. He needs to address the share price collapse and tell us why no-one is buying the product.
Price is so low now that If it goes to zero I won't lose too much more.
I'm not going to beat myself up about it, but i should have had some kind of stop loss in the 30's or 40's. On paper this is my biggest loss in 25 years.
M cap now is just under £20mil......what do they have in cash ? £10 Mil ?......so the market is valuing the product at about £10mil......doesn't look good
'' if you can make a heap of all your winnings
and risk it on one turn of pitch and toss,
and lose, and start again at your beginnings,
and never breath a word about your loss''..........If - Kipling
Https://venturebeat.com/ai/vida-diagnostics-raises-11-million-to-diagnose-lung-diseases-with-ai/
quite a good summary in above link where VIDA raised money in '22.
Company seems to have evolved from existing healthcare facilities in Iowa; more here:
https://www.thisisiowa.com/story/26/the-right-treatment-at-the-right-time/
Private company which makes it difficult to value, but maybe other posters can come up with something ? must be some way of finding revenues etc.
Basically they seem to be offering what POLX does ( and I should have known this if i had done my DD properly before investing here). They are using tMPR visualisation, so, topographic multi planar representation. Taking MRI scans CT scans and building up pictures using AI .
They seem to have built up a good customer base and, importantly, drug manufacturers are using their tech in their trials.
Obviously lots of questions; POLX must have known about VIDA but , I think, convinced many investors that no-one else was already operating in their space.
How many companies/ organisations will not buy POLX tech because they already have VIDA's ?
Were POLX hoping that their tech would surpass VIDA ? The collaboration RNS suggests recognition that this will not happen.
Lots to think about. I wonder how much of this will be addressed in upcoming presentation ?
If this collaboration is down to von Jacko then its a positive. A lot of techno gobbledigook in that RNS but worth researching VIDA over the w/e to get better understanding. The anticipated sales to the research hospitals don't appear to be happening and they were the easy targets.....at some point I will have to try to average down on this, either that or write the company off and look for a better investment
100m !! @ shpunken...... i would think £40m is very optimistic.....the company has no value if nobody wants the product.
I am surprised that we cannot make sales to pulmonary drug trial companies, this would seem to be a very good fit for a company trialling an asthma drug, for example. For treating disease, accurate pictures of gas movement thru the lungs would appear not to be critical to treatment process - hence no sales.
Any pulmonologists on the chatboard ? why would this tech be useful to you ?
Also noted that Angle (AGL) have released a good rns today and are up about the same amount we are down.....AGL, a company that has been compared to polx before
Nukem got the amati shares ?
not bought on open market by looks of sp
people buying the product will mean people buying the shares......8mths post approval and we have sweet fda....which is why we are where we are
What are u seeing @unhooked ?
I know what investors are not seeing - any sales
No sales means no company; if it continues like this
Fair comment Dulyred; and probably why we've had the CEO change. For hospitals to buy it, then there needs to be evidence that it can save them money; accurate graphics of lung function is very nice but if the treatment is still the same as before then no financial incentive to buy.
The case for drug development companies is stronger but obviously far smaller potential customer base. This and MRI makers themselves may drive some sales.
I think your window of 'a few more months' is also a fair timeframe for the new guy to vindicate his appointment
Interview with Dr Paul Jourdan that I missed when it was put up on you tube 6 days ago. Polx NOT discussed, at least, not on camera......draw your own conclusions. Some discussion of medical stocks and take up of new product by the health care industry was pertinent to this stock tho'.
Hopefully found a bottom at 20p, but raising at this level is going to hurt. Need sales, and soon.
also from companies website, as of March 2023 : about 40% belonging to ii's + bracco + nukem. Numbers haven't changed for a while.
https://www.polarean-ir.com/content/investors/shareholder-information
POLX need to be promoting exactly what their lung imaging can pick up. I don't think that it would be a better option than the CT scans talked about in referenced article because they are talking about picking up early stage cancer signs.
I don't think it would be a better option, but I don't know so. If POLX tech can be used to detect early lung cancer tumour growth then they need to be shouting it from the hospital roof tops !
lithium stocks in general have been on recovery run: ALL. BHL, SAV, ATM.....EMH to a lesser extent (whats going on there ? I ought to take more notice as its our geographical neighbour) but they have all fallen a long way in last year or so, like ZNWD
good news/ bad news ......depends which way u want to spin it. Does it look like the sales roll out is not rolling out ?......even after all that extra prep time ? Maybe this guy is supposed to kick start it a bit ; but he has been non-exec, so how much input did he have in that capacity? Probably needs that $300 per hour to motivate himself, luckily he is chairman of the remuneration committee so must know what he is worth :(
How's that cash burn going guys ?
Doesn't read well to me, but proof will be in the pudding if they start selling stuff.